JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on January 12, 2004; DOI: 10.1124/jpet.103.059824


0022-3565/04/3091-102-108$20.00
JPET 309:102-108, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.059824v1
309/1/102    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dupré, D. J.
Right arrow Articles by Stanková, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dupré, D. J.
Right arrow Articles by Stanková, J.

INFLAMMATION AND IMMUNOPHARMACOLOGY

Inverse Agonist Activity of Selected Ligands of the Cysteinyl-Leukotriene Receptor 1

Denis J. Dupré, Christian Le Gouill, Denis Gingras, Marek Rola-Pleszczynski, and Jana Stanková

Immunology Division, Department of Pediatrics, Faculty of Medicine, Université de Sherbrooke, Sherbrooke, Québec, Canada

Cysteinyl leukotrienes (CysLTs) are associated with several inflammatory processes, including asthma. Due to this association, considerable effort has been invested in the development of antagonists to the CysLT receptors (CysLT1R). Many of these molecules have been shown to specifically interact with CysLT1R, but little is known about their impact on the conformation of the receptor and its activity. We were especially interested in possible inverse agonist activity of the antagonists. Using a constitutively active mutant (N106A) of the human CysLT1R and the wild-type (WT) receptor coexpressed with the G{alpha}q subunit of the trimeric G protein, we were able to address this issue with ligands commonly used in therapy. We demonstrated that some of these molecules are inverse agonists, whereas others act as partial agonists. In cells expressing the CysLT1R mutant N106A exposed to Montelukast, Zafirlukast, or 3-[[3-[2-(7-chloroquinolin-2-yl)vinyl]phenyl]-(2-dimethylcarbamoylethylsulfanyl)methylsulfanyl] propionic acid (MK571), the basal inositol phosphate production was reduced by 53 ± 6, 44 ± 3, and 54 ± 4%, respectively. On the other hand, 6(R)-(4-carboxyphenylthio)-5(S)-hydroxy-7(E),9(E),11(Z),14(Z)-eicosatetraenoic acid (BayU9773) and 1-[2-hydroxy-3-propyl-4-[4-(1H-tetrazole-5-YL)-butoxy]-phenyl ethanone] (LY171883) acted as partial agonists and {alpha}-pentyl-3-[2-quinolinylmethoxy] benzyl alcohol (REV 5901) as a neutral antagonist. However, in cells expressing CysLT1R and G{alpha}q, all antagonists used had inverse agonist activity. The decrease in basal inositol phosphate production by ligands with inverse agonist activity could be inhibited by a more neutral antagonist, confirming the specificity of the reaction. We demonstrate here that Montelukast, MK571, and Zafirlukast can act as inverse agonists on the human CysLT1 receptor.


Received September 10, 2003; accepted December 18, 2003.

Address correspondence to: Dr. Jana Stankova, Immunology Division, Department of Pediatrics, Faculty of Medicine, Université de Sherbrooke, Sherbrooke, Québec, J1H 5N4 Canada. E-mail: jana.stankova{at}usherbrooke.ca




This article has been cited by other articles:


Home page
Am. J. Respir. Cell Mol. Bio.Home page
K. Parameswaran, K. Radford, A. Fanat, J. Stephen, C. Bonnans, B. D. Levy, L. J. Janssen, and P. G. Cox
Modulation of Human Airway Smooth Muscle Migration by Lipid Mediators and Th-2 Cytokines
Am. J. Respir. Cell Mol. Biol., August 1, 2007; 37(2): 240 - 247.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
L. Oliveira, C. M. Costa-Neto, C. R. Nakaie, S. Schreier, S. I. Shimuta, and A. C. M. Paiva
The Angiotensin II AT1 Receptor Structure-Activity Correlations in the Light of Rhodopsin Structure
Physiol Rev, April 1, 2007; 87(2): 565 - 592.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
Z. Ding, S. Kim, and S. P. Kunapuli
Identification of a Potent Inverse Agonist at a Constitutively Active Mutant of Human P2Y12 Receptor
Mol. Pharmacol., January 1, 2006; 69(1): 338 - 345.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
L. Parhamifar, B. Jeppsson, and A. Sjolander
Activation of cPLA2 is required for leukotriene D4-induced proliferation in colon cancer cells
Carcinogenesis, November 1, 2005; 26(11): 1988 - 1998.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.